Similar articles for PMID: 22043968

Year	Number of Results
2002	1
2006	5
2007	3
2008	5
2009	5
2010	4
2011	6
2012	12
2013	7
2014	8
2015	5
2016	6
2017	8
2018	6
2019	7
2020	6
2021	3
2022	2
2024	0

1

ADHD drugs and serious cardiovascular events in children and young adults.

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. Cooper WO, et al. N Engl J Med. 2011 Nov 17;365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1. N Engl J Med. 2011. PMID: 22043968 Free PMC article.

2

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. Habel LA, et al. JAMA. 2011 Dec 28;306(24):2673-83. doi: 10.1001/jama.2011.1830. Epub 2011 Dec 12. JAMA. 2011. PMID: 22161946 Free PMC article.

3

Cardiovascular events and death in children exposed and unexposed to ADHD agents.

Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S. Schelleman H, et al. Pediatrics. 2011 Jun;127(6):1102-10. doi: 10.1542/peds.2010-3371. Epub 2011 May 16. Pediatrics. 2011. PMID: 21576311 Free PMC article.

4

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Martinez-Raga J, et al. CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. CNS Drugs. 2013. PMID: 23160939 Review.

5

Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.

Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Dalsgaard S, et al. J Child Adolesc Psychopharmacol. 2014 Aug;24(6):302-10. doi: 10.1089/cap.2014.0020. Epub 2014 Jun 23. J Child Adolesc Psychopharmacol. 2014. PMID: 24956171 Free PMC article.

6

Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.

Houghton R, de Vries F, Loss G. Houghton R, et al. CNS Drugs. 2020 Jan;34(1):93-101. doi: 10.1007/s40263-019-00686-4. CNS Drugs. 2020. PMID: 31768949 Free PMC article.

7

Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.

Zhang L, Yao H, Li L, Du Rietz E, Andell P, Garcia-Argibay M, D'Onofrio BM, Cortese S, Larsson H, Chang Z. Zhang L, et al. JAMA Netw Open. 2022 Nov 1;5(11):e2243597. doi: 10.1001/jamanetworkopen.2022.43597. JAMA Netw Open. 2022. PMID: 36416824 Free PMC article.

8

Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Winterstein AG, et al. Pediatrics. 2007 Dec;120(6):e1494-501. doi: 10.1542/peds.2007-0675. Pediatrics. 2007. PMID: 18055666

9

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.

Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M. Winterstein AG, et al. BMJ. 2012 Jul 18;345:e4627. doi: 10.1136/bmj.e4627. BMJ. 2012. PMID: 22809800 Free PMC article.

10

Stimulants and Pediatric Cardiovascular Risk.

Zito JM, Burcu M. Zito JM, et al. J Child Adolesc Psychopharmacol. 2017 Aug;27(6):538-545. doi: 10.1089/cap.2015.0239. Epub 2016 Jun 3. J Child Adolesc Psychopharmacol. 2017. PMID: 27258470 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year